Literature DB >> 25316482

Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection.

Sohei Satoi1, Yoshiaki Murakami, Fuyuhiko Motoi, Kenichiro Uemura, Manabu Kawai, Masanao Kurata, Masayuki Sho, Ippei Matsumoto, Hiroaki Yanagimoto, Tomohisa Yamamoto, Masamichi Mizuma, Michiaki Unno, Yasushi Hashimoto, Seiko Hirono, Hiroki Yamaue, Goro Honda, Minako Nagai, Yoshiyuki Nakajima, Makoto Shinzeki, Takumi Fukumoto, A-Hon Kwon.   

Abstract

OBJECTIVE: The objective of the present study was to reappraise the clinical value of peritoneal washing cytology (CY) in 984 pancreatic ductal adenocarcinoma patients who underwent margin-negative resection.
METHODS: In a 2001-2011 database from seven high-volume surgical institutions in Japan, 69 patients (7%) had positive CY (CY+ group) indicative of M1 disease and 915 patients had negative CY (CY- group). Clinicopathological data and survival were compared between groups.
RESULTS: Significant correlations between CY+ and high CA19-9 level, pancreatic body and tail cancer, lymph node metastasis, and a lower frequency of R0 resection were observed. Overall survival (OS) of CY+ patients was significantly worse than that of CY- patients (median survival time [MST], 16 vs. 25 months; 3-year OS rate, 6 vs. 37%; p < 0.001). CY+ patients had a significantly higher rate of post-operative peritoneal carcinomatosis than CY- patients (48 vs. 21%; p < 0.001). Administration of adjuvant chemotherapy did not provide a favorable survival outcome to CY+ patients. The current study showed that patients with M1 disease had acceptable MST after margin-negative resection and a high incidence of peritoneal carcinomatosis within 3 years after surgery, resulting in decreased long-term survival. The development of a new strategy to control peritoneal carcinomatosis when surgical resection is performed in such patients is required.

Entities:  

Mesh:

Year:  2014        PMID: 25316482     DOI: 10.1007/s11605-014-2637-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer.

Authors:  Clancy J Clark; L William Traverso
Journal:  Am J Surg       Date:  2010-05       Impact factor: 2.565

2.  The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma.

Authors:  Cristina R Ferrone; Barbara Haas; Laura Tang; Daniel G Coit; Yuman Fong; Murray F Brennan; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer.

Authors:  Kenichiro Yamamoto; Shinya Shimada; Masahiko Hirota; Yasushi Yagi; Masakazu Matsuda; Hideo Baba
Journal:  Int J Oncol       Date:  2005-11       Impact factor: 5.650

5.  The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer.

Authors:  Ryuji Yoshioka; Akio Saiura; Rintaro Koga; Junichi Arita; Nobuyuki Takemura; Yoshihiro Ono; Junji Yamamoto; Toshiharu Yamaguchi
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

6.  Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.

Authors:  H Ishigami; J Kitayama; S Kaisaki; A Hidemura; M Kato; K Otani; T Kamei; D Soma; H Miyato; H Yamashita; H Nagawa
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

7.  8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Sjoerd Bruin; Henk Boot; Gooike van Slooten; Harm van Tinteren
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

8.  Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.

Authors:  Suguru Yamada; Shin Takeda; Tsutomu Fujii; Shuji Nomoto; Naohito Kanazumi; Hiroyuki Sugimoto; Hideki Kasuya; Yasuhiro Kodera; Tetsuro Nagasaka; Satoshi Morita; Akimasa Nakao
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

9.  Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study.

Authors:  Irene Thomassen; Valery E P P Lemmens; Simon W Nienhuijs; Misha D Luyer; Yvonne L Klaver; Ignace H J T de Hingh
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

10.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

View more
  8 in total

1.  Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study.

Authors:  Riccardo Casadei; Claudio Ricci; Giovanni Taffurelli; Anna Guariniello; Anthony Di Gioia; Mariacristina Di Marco; Nico Pagano; Carla Serra; Lucia Calculli; Donatella Santini; Francesco Minni
Journal:  J Gastrointest Surg       Date:  2016-07-14       Impact factor: 3.452

2.  Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy.

Authors:  Shimpei Maeda; Kyohei Ariake; Masahiro Iseki; Hideo Ohtsuka; Masamichi Mizuma; Kei Nakagawa; Takanori Morikawa; Hiroki Hayashi; Fuyuhiko Motoi; Takashi Kamei; Takeshi Naitoh; Michiaki Unno
Journal:  Surg Today       Date:  2019-11-25       Impact factor: 2.549

3.  Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sided Pancreatic Cancer.

Authors:  Toshiya Abe; Kenoki Ohuchida; Yoshihiro Miyasaka; Takao Ohtsuka; Yoshinao Oda; Masafumi Nakamura
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

4.  A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.

Authors:  Satoshi Nishiwada; Masayuki Sho; Jasjit K Banwait; Kensuke Yamamura; Takahiro Akahori; Kota Nakamura; Hideo Baba; Ajay Goel
Journal:  Gastroenterology       Date:  2020-05-04       Impact factor: 22.682

5.  Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies.

Authors:  Gianluca Tomasello; Michele Ghidini; Antonio Costanzo; Antonio Ghidini; Alessandro Russo; Sandro Barni; Rodolfo Passalacqua; Fausto Petrelli
Journal:  J Gastrointest Oncol       Date:  2019-04

Review 6.  Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis.

Authors:  Feng Cao; Jia Li; Ang Li; Fei Li
Journal:  Oncotarget       Date:  2017-02-28

7.  Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group.

Authors:  Sohei Satoi; Naminatsu Takahara; Tsutomu Fujii; Hiroyuki Isayama; Suguru Yamada; Yasushi Tsuji; Hideyo Miyato; Hironori Yamaguchi; Tomohisa Yamamoto; Daisuke Hashimoto; So Yamaki; Yousuke Nakai; Kei Saito; Hayato Baba; Toru Watanabe; Shigeto Ishii; Masamichi Hayashi; Keisuke Kurimoto; Hideaki Shimada; Joji Kitayama
Journal:  J Hepatobiliary Pancreat Sci       Date:  2022-01-07       Impact factor: 3.149

8.  A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.

Authors:  Satoshi Nishiwada; Masayuki Sho; Ya Cui; Kensuke Yamamura; Takahiro Akahori; Kenji Nakagawa; Minako Nagai; Kota Nakamura; Tadataka Takagi; Naoya Ikeda; Wei Li; Hideo Baba; Ajay Goel
Journal:  Int J Cancer       Date:  2020-09-12       Impact factor: 7.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.